Elevance Health, Inc.
ELV
$391.27
+0.58%
Elevance Health, Inc. is a leading health insurer in the United States, providing medical benefits to approximately 45 million members through employer, individual, and government-sponsored plans. The company holds a distinct competitive identity as the largest single provider of Blue Cross Blue Shield branded coverage, operating as a licensee in 14 states, and has expanded its reach in government programs like Medicaid and Medicare Advantage through strategic acquisitions. The current investor narrative is heavily influenced by regulatory developments in government healthcare programs, particularly the recent larger-than-expected 2027 Medicare Advantage payment increase from CMS, which has boosted sector-wide sentiment and revenue visibility for Elevance and its peers.…
ELV
Elevance Health, Inc.
$391.27
Investment Opinion: Should I buy ELV Today?
Rating & Thesis: ELV is a BUY for value-oriented investors seeking exposure to a stabilized managed care sector, based on its compelling valuation discount, strong recent momentum, and a clear regulatory tailwind that improves medium-term visibility. This aligns with the uniformly bullish stance of institutional analysts.
Supporting Evidence: The buy case is supported by four key data points: 1) Valuation at a discount (Forward P/E of 13.44x vs. likely higher sector median), 2) Strong technical momentum (+22.87% over 3 months), 3) A definitive positive catalyst (the 2027 Medicare Advantage payment increase), and 4) A robust financial backbone with $3.17B in TTM FCF and a manageable debt load (D/E 0.76). The stock trades near the low end of its historical P/E range, suggesting asymmetric upside if earnings stabilize.
Risks & Conditions: The two biggest risks are sustained earnings volatility and a failure to break key technical resistance at $408. This Buy rating would downgrade to Hold if quarterly net income fails to recover meaningfully from Q4's $547M level or if the stock fails to sustain momentum above $408. It would downgrade to Sell if margins deteriorate further, pushing the P/E multiple higher despite the low absolute price. Based on current data, the stock appears fairly valued to slightly undervalued relative to its improved prospects, but the valuation is not a deep value play until earnings consistency is proven.
Sign up to view all
ELV 12-Month Price Forecast
The AI assessment is cautiously bullish, with medium confidence. The combination of deep value, strong momentum, and a clear positive catalyst creates a favorable risk/reward setup. However, confidence is tempered by the severe earnings volatility, which must be resolved for the thesis to fully play out. The stance would upgrade to 'bullish with high confidence' on a confirmed breakout above $408 coupled with a quarterly earnings report showing net income recovery above $1 billion. It would downgrade to 'neutral' if the stock fails at resistance and earnings continue to exhibit wide quarterly swings.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $508.65 and implied upside of +30.0% versus the current price.
Average Target
$508.65
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$313 - $509
Analyst target range
Analyst coverage for ELV is limited, with data indicating only 6 analysts providing estimates, which is low for a company of its market cap ($77.8 billion). This suggests it may be under-followed relative to its size, potentially leading to less efficient price discovery. The available data points to a consensus revenue estimate for the upcoming period of $237.41 billion, with a range from $231.88 billion to $244.54 billion, indicating a relatively tight spread and moderate growth expectations. The full target range and explicit buy/hold/sell distribution are not available in the provided data, making it difficult to gauge the precise consensus sentiment and implied upside. However, the recent institutional ratings show a uniformly bullish stance, with firms like Mizuho, JP Morgan, Wells Fargo, and Barclays all maintaining 'Overweight' or 'Buy' equivalents throughout early 2026, with Wolfe Research upgrading to 'Outperform' in January. This pattern of sustained bullish ratings from major firms, in the absence of downgrades, signals strong institutional conviction in the stock's prospects, likely tied to the improved Medicare payment outlook and the company's market position.
Bulls vs Bears: ELV Investment Factors
The evidence currently tilts bullish, driven by a powerful technical reversal, attractive valuation, a clear positive regulatory catalyst, and unanimous institutional buy ratings. However, the bear case is anchored by severe and concerning earnings volatility, which directly challenges the stability required to justify a higher valuation multiple. The single most important tension in the investment debate is whether the company can translate the favorable Medicare revenue backdrop into consistent, predictable quarterly earnings, or if operational inefficiencies and cost pressures will continue to cause dramatic profit swings that erode investor confidence.
Bullish
- Strong Technical Momentum & Reversal: ELV has surged +22.87% over the past 3 months, decisively breaking out from its 52-week low of $273.71 and now trades at $393.19, near its 52-week high of $408. This powerful reversal, significantly outperforming the S&P 500, signals a major bullish shift in sentiment, likely fueled by positive sector catalysts like the favorable Medicare payment update.
- Attractive Valuation vs. Sector & History: The stock trades at a trailing P/E of 13.73x and a forward P/E of 13.44x, which is below typical healthcare plan multiples. Its P/S ratio of 0.39x and EV/Sales of 0.40x represent a significant discount to revenue. Historically, its current P/E is near the lower end of its range, suggesting room for multiple expansion if earnings stabilize.
- Solid Financial Foundation & Cash Flow: Elevance maintains a strong balance sheet with a moderate debt-to-equity ratio of 0.76 and a healthy current ratio of 1.24. Most importantly, it generates robust free cash flow of $3.17 billion (TTM), providing ample liquidity for dividends (27% payout ratio), share buybacks, and strategic investments, mitigating financial risk.
- Positive Regulatory Catalyst for Core Business: The recent larger-than-expected 2027 Medicare Advantage payment increase from CMS directly boosts revenue visibility for Elevance's substantial government-sponsored plans. This regulatory tailwind addresses a key sector overhang and underpins the improved institutional sentiment and recent stock rally.
Bearish
- Severe Earnings Volatility & Margin Pressure: Q4 2025 net income plummeted to $547 million (1.10% net margin) from $1.19 billion (2.34% net margin) in Q3, with gross margin compressing from 24.79% to 23.48%. This extreme quarterly volatility in profitability raises significant concerns about earnings predictability and operational efficiency, casting doubt on forward estimates.
- Limited Analyst Coverage & Price Discovery: With only 6 analysts providing estimates for a $77.8 billion market cap company, ELV appears under-followed. This low coverage can lead to less efficient price discovery, increased volatility on news, and a lack of a clear consensus target price to anchor valuation, increasing investment uncertainty.
- Testing Major Technical Resistance: The stock is currently trading at approximately 88% of its 52-week range, pressing against the key resistance level of $408.00. Failure to break above this level could trigger a technical pullback or consolidation, especially after the sharp 3-month rally of nearly 23%, suggesting near-term upside may be limited.
- Subdued Long-Term Price Performance: Despite the recent surge, ELV's 1-year price change is a modest +3.33%, significantly underperforming the S&P 500's +28.21% gain. This long-term underperformance, evidenced by a -24.88 relative strength over one year, highlights persistent investor skepticism that the recent rally must now overcome.
ELV Technical Analysis
The prevailing price trend for ELV is one of significant volatility within a defined range, culminating in a strong recovery. The stock's 1-year price change is a modest +3.33%, but this masks a dramatic journey from a 52-week low of $273.71 to a high of $408.00. With a current price of $393.19, the stock is trading at approximately 88% of its 52-week range, indicating it is near recent highs and testing a major resistance level, which suggests strong momentum but also potential for a pullback if the resistance holds. Recent momentum has been exceptionally strong, with the stock surging +22.87% over the past 3 months and +4.40% over the past month, significantly outperforming the S&P 500's +10.28% and +6.31% over the same periods, respectively. This powerful short-term uptrend, diverging from the flat 1-year performance, signals a decisive bullish reversal from the lows set in early March 2026, likely driven by positive sector catalysts. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $408.00 and primary support at the 52-week low of $273.71. A confirmed breakout above $408 would signal a new bullish phase, while a failure could lead to consolidation. The stock's beta of 0.67 indicates it is approximately 33% less volatile than the broader market, which is typical for a large-cap managed care company and suggests it may offer relative stability during market swings, though the recent price action has been anything but stable.
Beta
0.67
0.67x market volatility
Max Drawdown
-34.7%
Largest decline past year
52-Week Range
$274-$408
Price range past year
Annual Return
+3.2%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +5.2% | +5.0% |
| 3m | +36.6% | +10.7% |
| 6m | +18.3% | +10.0% |
| 1y | +3.2% | +26.5% |
| ytd | +10.5% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Elevance's revenue trajectory shows steady growth, with Q4 2025 revenue of $49.75 billion representing a solid 9.47% year-over-year increase. Segment data reveals the Health Benefits segment, at $41.84 billion, is the dominant revenue driver, while the Carelon Services segment contributes $18.66 billion, indicating a diversified model beyond pure insurance. The multi-quarter trend shows revenue has grown sequentially from $48.89 billion in Q1 2025 to the Q4 level, supporting a stable growth investment case. The company is profitable but exhibits significant quarterly volatility in earnings; Q4 2025 net income was $547 million on a gross margin of 23.48%, but this was a sharp decline from the robust Q3 net income of $1.19 billion and a gross margin of 24.79%. This compression in Q4 profitability, with the net income ratio falling to 1.10% from 2.34% in Q3, suggests potential seasonality or one-time cost pressures, requiring close monitoring of margin sustainability. The balance sheet and cash flow position appear solid, with a debt-to-equity ratio of 0.76 indicating moderate leverage, a current ratio of 1.24 showing sufficient short-term liquidity, and a trailing twelve-month free cash flow of $3.17 billion. The Return on Equity of 12.90% demonstrates adequate capital efficiency. The strong free cash flow generation provides ample internal funding for growth initiatives, dividends (payout ratio 27.00%), and share repurchases, mitigating financial risk.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given that Net Income is positive, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 13.73x, while the forward PE is slightly lower at 13.44x, indicating the market expects modest earnings growth. The narrow gap between trailing and forward multiples suggests consensus expectations are for stable, rather than explosive, near-term profit expansion. Compared to sector averages, ELV's valuation appears modest. Its trailing PE of 13.73x and forward PE of 13.44x are below typical healthcare plan multiples, which often trade in the mid-teens to low-20s. Furthermore, its Price-to-Sales ratio of 0.39x and EV-to-Sales of 0.40x indicate a significant discount to revenue, which could be justified by the industry's thin net margins but may also present a value opportunity if profitability normalizes. Historically, ELV's current trailing PE of 13.73x sits near the lower end of its own historical range observed over the past several years, where multiples have frequently been above 15x and even exceeded 30x during periods of compressed earnings. Trading near historical lows suggests the market may be pricing in conservative expectations or past profitability concerns, leaving room for multiple expansion if earnings demonstrate more consistent strength.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on extreme earnings volatility and margin compression. Q4 2025 net income fell 54% sequentially to $547 million, with the net margin collapsing to 1.10% from 2.34%. This unpredictability makes forecasting difficult and suggests potential underlying cost control or medical cost trend issues. While the balance sheet is solid (D/E 0.76, Current Ratio 1.24), the company's valuation relies on profit stabilization; continued volatility could prevent multiple expansion despite low absolute P/E.
Market & Competitive Risks include valuation stagnation and regulatory dependency. ELV trades at a discount to sector peers (P/E 13.73x), but if earnings remain volatile, this discount may persist or widen. The stock's beta of 0.67 indicates lower market volatility, but its own price has been highly volatile, with a 52-week range from $273.71 to $408.00. The recent rally is almost entirely predicated on positive Medicare news; any future regulatory setbacks or increased competition in government segments could quickly reverse gains.
Worst-Case Scenario involves a return to prior lows driven by an earnings miss coupled with a negative regulatory shift. If Q4 2025's margin weakness proves not to be an anomaly but a trend, and a future CMS update disappoints, investor sentiment could rapidly sour. This could trigger a sell-off back toward the 52-week low of $273.71, representing a potential downside of approximately -30% from the current price of $393.19. The stock's historical max drawdown of -35.95% provides a precedent for such severe declines.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility: Dramatic quarterly profit swings (Q4 net income of $547M vs. Q3's $1.19B) challenge predictability. 2) Regulatory Dependency: Future changes to Medicare/Medicaid reimbursement can swiftly impact revenue, despite the recent positive news. 3) Technical Resistance: The stock is testing a major resistance level at $408; failure could lead to a pullback. 4) Low Analyst Coverage: Only 6 analysts follow this large-cap stock, which can lead to less efficient price discovery and increased volatility on news.
The 12-month outlook for ELV is framed by three scenarios with associated probabilities. The Base Case (50% probability) sees range-bound trading between $390 and $420, assuming earnings stabilize modestly. The Bull Case (30% probability) targets $425 to $460, requiring a breakout above $408 and a clear recovery in quarterly profits. The Bear Case (20% probability) risks a decline to $275-$320 if earnings deteriorate further and regulatory sentiment sours. The most likely scenario is the Base Case, predicated on the assumption that extreme earnings volatility persists but is offset by the valuation floor and sector tailwinds.
ELV appears fairly valued to slightly undervalued based on current metrics. Its trailing P/E of 13.73x and forward P/E of 13.44x are below typical healthcare plan multiples, and its Price-to-Sales ratio of 0.39x indicates a significant discount to revenue. Historically, its P/E is near the lower end of its own range. The market is pricing in conservative expectations and past profitability concerns. If earnings demonstrate consistency, there is clear room for multiple expansion, suggesting the stock is not overvalued and may be undervalued relative to its improved fundamental outlook.
ELV presents a compelling buy case for value-oriented investors comfortable with some volatility. The stock trades at an attractive valuation (forward P/E 13.44x) below its sector and historical averages, has surged 22.87% in three months on a positive regulatory catalyst, and enjoys unanimous bullish ratings from major institutions. The key risk is severe earnings volatility, as seen in Q4's 54% sequential profit drop. It is a good buy for those who believe the company will stabilize profits and that the Medicare Advantage tailwind will support multiple expansion, but may be too volatile for conservative income investors.
ELV is more suitable for a medium- to long-term investment horizon (12+ months) rather than short-term trading. While recent momentum is strong, the stock's low beta (0.67) and value characteristics are better aligned with a patient approach that allows time for earnings consistency to develop and for the Medicare Advantage tailwind to fully materialize in financial results. The quarterly volatility makes it challenging for short-term traders. A minimum holding period of 1-2 years is suggested to potentially realize the valuation re-rating and benefit from the company's strong free cash flow generation through dividends and buybacks.